Featured Companies
Dialogic, DLGC, Profile, Summary
Dialogic | DLGC | Profile | Summary
Dialogic (DLGC) develops products and technologies that enable operators to provide – and subscribers to enjoy - an enhanced mobile experience. Whether our products are used in mobile value-added service solutions or to transform, connect and optimize communications services on a wide variety of networks, Dialogic understands that “mobile experience matters.™” Our technology touches two billion mobile subscribers a day, and our network solutions carry 15 billion minutes of traffic per month.
Dialogic, the Network Fuel™ company, inspires the world’s leading service providers and application developers to elevate the performance of media-rich communications across the most advanced networks. We boost the reliability of any-to-any network connections, supercharge the impact of applications and amplify the capacity of congested networks. Forty-eight of the world’s top 50 mobile operators and nearly 3,000 application developers rely on Dialogic to redefine the possible and exceed user expectations.
High performance networks and applications demand Network Fuel in the following areas:
Any to Any Networking:
Dialogic seamlessly and efficiently connecting disparate networks and/or value-added services platforms based on a complex array of networks and network protocols such as TDM, IP, SIP and IMS. Dialogic technologies enable media-rich communications, including video, voice and data, to flow uninterrupted between Service Providers and Application Developers and their end-users while ensuring the lowest operating costs and most optimal customer experience.
Contact Center Transformation:
As contact centers transition from TDM to IP, from premise-based to cloud/hosted or from fragmented to centralized to decentralized, Dialogic technologies enable contact center operators to maximize their investment by integrating multi-modal media-rich communications in a secure and optimized fashion. Contact centers empowered by Dialogic technologies perform better and run more cost effectively.
Unified Communications for Service Providers:
Through unique partnerships with market leaders in Unified Communications, Dialogic is enabling Service Providers to better leverage their investments in network switching infrastructure and offer a broader array of value-added services including hosted IP-PBX via PC and mobile, video calling and more sophisticated Class 5 services over a more secure and cost-optimized network. This collaboration enables Service Providers to more effectively compete with traditional Enterprise telephony vendors while expanding customer share of wallet.
Application Enablement:
The company is a recognized leader in software-based solutions that enable Application Developers to rapidly develop and monetize a wide array of value-added services such as messaging, SMS, video calling, ringtones, lawful intercept and location-based services. Dialogic customers are able to continually offer innovative solutions and benefit from our extensive capabilities in mixing media-rich communications, transitioning to virtualized or cloud-based architectures and deploying highly available and scalable platforms or services. The Dialogic Solution Showcase features market-tested, revenue generating solutions for service providers and enterprises. Each solution is recognized for its innovative nature as well as its market-proven reliability, ease of deployment and scalability.
Source: Dialogic, OxBridge Research, Daily Stock Deal, OTC King
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Green Earth Technologies, GETG, Profile, Summary
Green Earth Technologies | GETG | Profile | Summary
Green Earth Technologies, GETG, markets an array of branded, environmentally-friendly, bio-based performance and cleaning products to the automotive, outdoor power equipment and marine markets. They also sell an innovative, EPA approved surface washing agent, which can be used to clean-up oil rigs and spills.
All of Green Earth Tech's products are produced for them under well defined contracts with domestic manufacturers. The “green” base of the performance products is comprised of animal fats, plant oils and vegetable oils. These biodegradable bases replace traditional petroleum and chemical derived bases typically used to make motor oils, cleaning solutions and other consumer products without compromising performance or value. The products are positioned to deliver comparable or superior performance at competitive prices.
Their family of G-branded products are grouped under the following categories: G-OIL, G-FUEL, G-CLEAN, G-GLASS, and G-MARINE. These products are offered in a wide range of automotive, marine and outdoor power equipment categories.
Highlights:
? Offerings in alternative eco-friendly motor/marine oil and cleaning products diversified across auto, boat, and power equipment lines.
? Green Earth Technologies Inc. is one of only a handful of companies that are EPA-approved for their surface washing agent which helps clean up oil spills.
? Green Earth Technologies Inc. is one of the first companies that are approved to use USDA’s new product label ‘Certified Bio-based Product’. The program was enacted by the Congress to help reduce America’s dependence on foreign oil. Under this program Federal Agencies are required to give preference to bio based products when they make procurements.
? Distribution through top-tier retailers like Home Depot, Walmart, Strauss Auto, and Canadian Tire to name a few.
? TTI, a premier manufacturer with brands like Hoover, and Dirt Devil owns 23.5% of Green Earth Technologies.
? Strong, seasoned management team with technology, consumer brand building, and mergers/acquisitions experience.
? Little to no debt.
? With projected sales of close to $200 million in 5-years time and applying a comparable industry multiple, we believe the shares are fairly valued at $.75 even using a conservative discount factor of 30%.
G-OIL 5W-30 Bio-Based Synthetic Motor Oil
Green Earth's G-OIL Motor Oil was the world's first API SM certified bio-based motor oil.
G-OIL 4-Cycle GREEN Engine Oil & 2-Cycle Bio-Based Synthetic GREEN Engine Oil
Marine cleaning products are used for washing the boat and maintaining and cleaning the hull and bottoms, bilge, galleys, windows and engine rooms. Marine performance products maintain and protect a boat’s engine. The size of the recreational marine market was roughly $33 billion in 2008.
GREEN EARTH IN NEWS
· G-CLEAN® Welcomed into the NASCAR Green Family
· Green Earth Technologies' G-OIL® named "Official Motor Oil" of Daytona International Speedway and the DAYTONA 500®
· G-OIL Flies High At Daytona, Mike Bliss, John Smith Carry G-OIL into Daytona Competition
· Green Earth Technologies, Inc. announces the distribution of their outdoor power equipment oils,lubricants and stabilizers in lawn & garden departments at Walmart.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
OxBridge Research initiates coverage of Teryl Resources,TRC.V, with a price target of 14 cents
Teryl Resources, TRC.V / TRYLF
OxBridge Research, a leading provider of investment research and investor relations services, today announced that it has initiated coverage of Teryl Resources with a price target of 14 cents.
Teryl Resources is a Junior Gold Mining company with assets in Fairbanks Mining District in Alaska and British Columbia. The Fairbanks Mining District is one of Alaska’s largest gold producing areas – gold production of over 40 million ounces.
The 31 page Report covers, Teryl's properties, its various Joint Venture partners including Kinross Gold Corporation (KGC) and Linux Gold Corp. (LNXGF) and future Gold market outlook.
The full Report is available for download for FREE at http://www.oxbridgeresearch.com/ and http://www.terylresources.com/ in addition to this Initiation Report, OxBridge Research will also provide ongoing coverage and event-based research updates on the Company.
Company Description
Teryl Resources Corp., TRC.V, is an early stage Canadian junior precious metals acquisition, exploration, and development company which holds interests in gold and silver properties in Alaska and British Columbia, Canada. Click here for complete Executive Summary
The Company is an accomplished explorer with a proven track record of exploration, development, and marketing its properties to mining majors. The Company has three properties in Alaska and one property in British Columbia. Teryl’s properties in Alaska are in the Fairbanks Mining District and include the West Ridge Property, Fish Creek Property, and Stepovich Property. Learn more about Teryl's strategy, see the Investment Highlights
The Fairbanks Mining District is one of the largest gold producing areas in Alaska. In 2011, Teryl sold its 20% stake in Gil Properties to Kinross Gold for US$15 million. see Teryl's Valuation
The Company’s single property in British Columbia is its Silverknife Property. Teryl also has oil and gas properties in Texas and Kentucky. To date, Teryl has spent over $2.2 million on exploration of its properties. Find out why the Analyst thinks the stock is undervalued, read Investment Thesis now
Sources: Teryl Resources Corp., Kinross Gold Corp., Linux Gold Corp., SilverCorp.
Forward-looking statements:-The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements, including those described in the Company's Financial Statements, Management Discussion and Analysis and Material Change Reports filed with the Canadian Securities Administrators and available at www.sedar.com, and the Company's 20-F annual report filed with the United States Securities and Exchange Commission at www.sec.gov.
This profile/research report/email letter/blog/posting in forums/social-media/t/f does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities of the Company have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclosure/Disclaimer:-OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment of seven thousand dollars in compensation from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including consultation, publication, advertisement and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners. It's YOUR money -Invest WISELY TM
Titan Pharmaceuticals, TTNP, Profile, Summary
Titan Pharmaceuticals | TTNP | Profile | Summary
Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders.
Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations.
The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.
Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes.
Continuous Drug Delivery Technology
The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.
This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.
Strategic Alliances
In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.
Novartis Pharma, AG, has licensed the rights to commercialize Fanapt in the U.S. and Canada, and commenced marketing the product in the U.S. in Q1, 2010. Titan is entitled to receive a royalty of 8-10% on the global net sales of this product. Titan does not incur any expenses related to this product.
Source: Titan Pharmaceuticals, OxBridge Research, Daily Stock Deals, OTC King. PSM
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. OTCking.com is an OxBridge affiliate/partner website.
Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement,and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it
OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.
It's YOUR money - Invest WISELY TM
OTCKing
Feed Entries
